Phase 2Active, not recruiting
ASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positive Chronic Myeloid Leukemia in Chronic Phase
Phase II Study Assessing Safety and Clinical Activity of the Combination of ASTX727 With Dasatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
- Sponsor
- M.D. Anderson Cancer Center (Academic or other)
- Enrolment
- 39 enrolled
- Conditions
- Chronic Phase Chronic Myelogenous Leukemia; Philadelphia Chromosome Positive; BCR-ABL1 Positive Chronic Myelogenous Leukemia; BCR-ABL1 Positive
- Interventions
- Dasatinib; Decitabine and Cedazuridine
- Ages
- children, adults, older adults
- Registry
- NCT05007873
Full record on ClinicalTrials.gov
From the registry
This phase II trial studies the effect of ASTX727 and dasatinib in treating patients with newly diagnosed Philadelphia chromosome or BCR-ABL positive chronic myeloid leukemia in chronic phase. Philadelphia chromosome positive and BCR-ABL positive are types of genetic mutations (changes). Chemotherapy drugs, such as ASTX727, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Dasatinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. ASTX727 and dasatinib may help to control Philadelphia chromosome-positive chronic myeloid leukemia or BCR-ABL positive chronic myeloid leukemia in chronic phase.
Primary outcomes
- Rate of molecular response 4 (MR4)
History
Primary completion expected
Last registry update
Started
Registered